NIG
KRYS icon

NFJ Investment Group’s Krystal Biotech KRYS Stock Holding History

NFJ Investment Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,249
Closed -$2.03M – 244
2025
Q4 		$2.03M Sell
8,249
-363
-4% -$76.4K 0.07% 167
2025
Q3 		$1.52M Buy
+8,612
New +$1.29M 0.05% 191

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NFJ Investment Group's KRYS Position: Q1 2026 in Review

NFJ Investment Group sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 8,249 shares — an estimated $2.03M sold.

NFJ Investment Group first reported a position in KRYS in Q3 2025 and held it in 2 quarters. The position peaked at $2.03M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • NFJ Investment Group reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • NFJ Investment Group sold 8,249 Krystal Biotech shares in Q1 2026, an estimated $2.03M.
  • NFJ Investment Group first reported a position in Krystal Biotech in Q3 2025 and held it in 2 quarters.
  • NFJ Investment Group's Krystal Biotech position peaked at $2.03M in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on NFJ Investment Group's 13F filing for Q1 2026, filed 13 May 2026.